Literature DB >> 956646

Colchicine-sensitive structures and lymphocyte activation.

W C Greene, C M Parker, C W Parker.   

Abstract

The possible modulatory role of microtubules or closely related colchicine-sensitive structures in the response of human lymphocytes to mitogenic lectins was investigated. Colchicine (0.1 to 10 muM) AND VINBLASTINE (0.1 TO 10 MUM) inhibited early [14C]-aminoisobutyric acid and late [3H]-thymidine uptake in phytohemagglutinin-and concanavalin A-stimulated human lymphocytes but failed to alter 45Ca uptake. Lumicolchicine, an inactive congener of colchicine, was ineffective in all three systems. Both microtubular agents accentuated and prolonged the early cyclic AMP response to lectin. Little or no alteration in cyclic AMP levels was seen with colchicine or vinblastine alone or in combination with PGE (10MUM) or epinephrine (1muM) suggesting that the effect on cyclic AMP metabolism is largely selective for lectin stimulation. Neither microtunular agent altered 125I-concanacalin A binding. Since the inhibition of DNA synthesis was throughout the culture period and early aminoisobutyric acid uptake is affected, it appears that these agents are acting on an early event, or events, in the activation sequence. Although the mechanism of the inhibition is not known, the effect of colchicine and vinblastine in prolonging the cyclic AMP response to lectin may be involved. Alternatively, alterations in microtubules assembly may exert effects on membrane architecture interfering with propagation of the stimulus from the membrane to the cell interior.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 956646

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

Review 1.  Is signal transduction modulated by an interaction between heterotrimeric G-proteins and tubulin?

Authors:  R Ravindra
Journal:  Endocrine       Date:  1997-10       Impact factor: 3.633

2.  Effect of in vitro colchicine and oral theophylline on suppressor cell function of asthmatic patients.

Authors:  D Ilfeld; S Kivity; E Feierman; M Topilsky; O Kuperman
Journal:  Clin Exp Immunol       Date:  1985-08       Impact factor: 4.330

Review 3.  Tubulin, actin and heterotrimeric G proteins: coordination of signaling and structure.

Authors:  Jeffrey M Schappi; Aleksandar Krbanjevic; Mark M Rasenick
Journal:  Biochim Biophys Acta       Date:  2013-09-23

4.  Human lung tissue and anaphylaxis. Evidence that cyclic nucleotides modulate the immunologic release of mediators through effects on microtubular assembly.

Authors:  M Kaliner
Journal:  J Clin Invest       Date:  1977-10       Impact factor: 14.808

5.  Antagonism by taxol of effects of microtubule-disrupting agents on lymphocyte cAMP metabolism and cell function.

Authors:  G Wolberg; C R Stopford; T P Zimmerman
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

6.  Classification of chemotherapeutic agents based on their differential in vitro effects on dendritic cells.

Authors:  Hiroaki Tanaka; Hironori Matsushima; Norikatsu Mizumoto; Akira Takashima
Journal:  Cancer Res       Date:  2009-08-25       Impact factor: 12.701

7.  Differential sensitivity of insulin- and adaptive-regulation-induced system A activation to microtubular function in skeletal muscle.

Authors:  A Gumà; A Castelló; X Testar; M Palacín; A Zorzano
Journal:  Biochem J       Date:  1992-01-15       Impact factor: 3.857

8.  Inhibition by colchicine of changes in amino acid transport and initiation of DNA synthesis in regenerating rat liver.

Authors:  P R Walker; J F Whitfield
Journal:  Proc Natl Acad Sci U S A       Date:  1978-03       Impact factor: 11.205

9.  Colchicine use for familial Mediterranean fever. Observations associated with long-term treatment.

Authors:  R S Peters; T J Lehman; A D Schwabe
Journal:  West J Med       Date:  1983-01

10.  A colchicine-sensitive uptake system in Morris hepatomas.

Authors:  R Tauber; W Reutter
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.